Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors

Simple item page
dc.contributor.authorSezgin C.
dc.contributor.authorKarabulut B.
dc.contributor.authorUslu R.
dc.contributor.authorSanli U.A.
dc.contributor.authorGoksel G.
dc.contributor.authorYuzer Y.
dc.contributor.authorGoker E.
dc.date.accessioned2024-07-22T08:23:43Z
dc.date.available2024-07-22T08:23:43Z
dc.date.issued2005
dc.description.abstractObjective. Most patients with pancreatic cancer show an inoperable locally advanced/ metastatic tumour at the time of diagnosis. The present study was aimed at determining the prognostic factors in patients with advanced pancreatic carcinoma treated with gemcitabine. Material and methods. Sixty-seven unresectable or metastatic pancreatic cancer patients treated with gemcitabine were included in the study and a total of 258 cycles of treatment were applied. Results. The overall response rate was 5%. Thirty-one percent of the patients had stable disease, whereas progressive disease was seen in 49%. Clinical benefit response rate was 15%. The median duration of response was 7.3 months. Median progression-free survival was 3 months, while median overall survival was 9 months. Univariate analysis revealed that worse results were found in patients with performance status (PS) =2, and in patients with primary tumour location in the body or tail of the pancreas (p <0.05). Multivariate analysis of data revealed that the most important factor was PS of the patient, as the patients with PS =2 had worse results than the patients with PS =0-1 (p <0.05). Conclusions. Low PS is a negative predictive factor for the survival of patients with advanced pancreatic carcinoma treated with gemcitabine. © 2005 Taylor & Francis.
dc.identifier.DOI-ID10.1080/00365520510023819
dc.identifier.issn15027708
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19669
dc.language.isoEnglish
dc.subjectAdult
dc.subjectAged
dc.subjectAntimetabolites, Antineoplastic
dc.subjectCarcinoma
dc.subjectDeoxycytidine
dc.subjectDisease-Free Survival
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHealth Status Indicators
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPancreatic Neoplasms
dc.subjectRetrospective Studies
dc.subjectSurvival Rate
dc.subjectTreatment Outcome
dc.subjectgemcitabine
dc.subjectadult
dc.subjectadvanced cancer
dc.subjectaged
dc.subjectanemia
dc.subjectanorexia
dc.subjectarticle
dc.subjectcancer chemotherapy
dc.subjectcancer patient
dc.subjectcancer survival
dc.subjectdiarrhea
dc.subjectdisease course
dc.subjectdisease free survival
dc.subjectdrug hypersensitivity
dc.subjectdrug response
dc.subjectfemale
dc.subjectfever
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmetastasis
dc.subjectmultivariate analysis
dc.subjectneutropenia
dc.subjectpancreas carcinoma
dc.subjectperformance
dc.subjectpriority journal
dc.subjectprognosis
dc.subjectthrombocytopenia
dc.subjecttumor localization
dc.subjectunivariate analysis
dc.titleGemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors
dc.typeArticle

Files

Collections

Scopus Koleksiyonu